Use case

Longevity and anti-aging

Which peptides have real evidence behind longevity and anti-aging claims?

Context

No peptide is approved for slowing aging. Longevity claims should be read against what the strongest programs actually proved, and against basic prevention with far better evidence.

Compare epitalon, MOTS-c, SS-31, NAD+, and thymalin: a category where one compound reached a narrow FDA approval, one has strong animal data, and the rest rest on lineage literature.

Peptides compared

Mostly preclinical

Epitalon

A short AEDG tetrapeptide discussed in circadian, melatonin, telomere, retina, and longevity contexts, where public claims often exceed direct clinical evidence.

Investigational / not approved

Limited human evidence

MOTS-c

A mitochondrial-derived peptide with human biomarker and association data, preclinical metabolic mechanism work, and no posted intervention results yet.

Investigational / not approved

Moderate human evidence

SS-31 / Elamipretide

A cardiolipin-targeting tetrapeptide with FDA accelerated approval under the Forzinity brand for a narrow Barth syndrome indication, plus mixed or negative non-Barth development areas.

Approved for specific use

Limited human evidence

NAD+

A peptide-adjacent coenzyme reference that separates NAD+ cell biology from clinic, infusion, oral, nasal, and product-quality claims.

Not FDA-approved for listed uses

Limited human evidence

Thymalin is a thymus-extract peptide mixture with Soviet-era drug registration and gerontology literature behind it. Modern controlled evidence is lacking, and products outside that lineage are unverified.

Varies by product and jurisdiction

Sources

1.
PubMed. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells 2003.
PMID:12937682 Accessed 2026-06-08.
Human somatic cell source for telomerase/telomere mechanism; not a clinical longevity outcome.
2.
PubMed. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance 2015.
PMID:25738459 Accessed 2026-06-08.
Preclinical/metabolic mechanism source.
3.
ClinicalTrials.gov. ClinicalTrials.gov record NCT07505745 2026.
NCT07505745 Accessed 2026-06-08.
Recruiting/no posted-results trial record at the 2026-06-08 source check.
4.
FDA. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome 2025.
Accessed 2026-06-09.
FDA announcement for accelerated approval of Forzinity (elamipretide) injection for Barth syndrome in patients weighing at least 30 kg.
5.
PubMed. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD 2019.
PMID:31572171 Accessed 2026-06-17.
Small human IV NAD+ metabolome pilot; used for study-exposure context, not as evidence of wellness efficacy.
6.
FDA. FDA reminds compounders to use ingredients suitable for sterile compounding 2024.
Accessed 2026-06-09.
FDA alert describing ingredient-suitability concerns for sterile compounded products, including NAD+ examples and reported adverse events consistent with endotoxin-related reactions.
7.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.